Johnson & Johnson (NYSE:JNJ)

99.20
Data as of Apr 15
 +2.06 / +2.12%
Today’s Change
81.71
Today|||52-Week Range
99.38
+8.31%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$273.0B

Company Description

Johnson & Johnson operates as an investment holding company with interests in health care products. It engages in research and development, manufacture and sale of personal care hygienic products, pharmaceuticals and surgical equipment. The company, through its subsidiaries operates in three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products, and wellness and prevention platforms. The baby care franchise includes the JOHNSON'S Baby line of products. Major brands in the skin care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; DABAO; and VEND‘ME product lines. Brands in the oral care franchise include the LISTERINE and REMBRANDT oral care lines, as well as REACH interdental products. The wound care franchise includes BAND-AID brand adhesive bandages and NEOSPORIN First Aid products. Major brands in the women's health franchise are CAREFREE pantiliners; o.b. tampons and STAYFREE sanitary protection products. The principal nutritional line is SPLENDA No Calorie Sweetener. Over-the-counter medicines include the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller. The Pharmaceutical segment includes products in the anti-infective, antipsychotic, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, neurology, oncology, pain management, thrombosis and vaccines areas. The products in this segment include REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; STELARA (ustekinumab), a treatment for adults with moderate to severe plaque psoriasis; SIMPONI (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis; VELCADE (bortezomib), a treatment for multiple myeloma; ZYTIGA (abiraterone acetate), a treatment for metastatic castration-resistant prostate cancer; PREZISTA (darunavir), INTELENCE (etravirine) and EDURANT (rilpivirine), treatments for HIV/AIDS; INCIVO (telaprevir), for the treatment of hepatitis C; NUCYNTA ER (tapentadol) extended release tablets, a treatment for moderate to severe chronic pain in adults and neuropathic pain associated with diabetic peripheral neuropathy in adults; INVEGA SUSTENNA (paliperidone palmitate), for the acute and maintenance treatment of schizophrenia in adults; INVEGA (paliperidone) extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; RISPERDAL CONSTA (risperidone), a treatment for the management of Bipolar I Disorder and schizophrenia; XARELTO (rivaroxaban), an oral anticoagulant for the prevention of thrombosis following total hip or knee replacement surgery, for the prevention of stroke in patients with atrial fibrillation, for the treatment of pulmonary embolism (PE) or deep vein thrombosis (DVT) or to reduce the risk of recurrence of DVT or PE following an initial six months of treatment for acute venous thromboembolism; PROCRIT (epoetin alfa, sold as EPREX), to stimulate red blood cell production; LEVAQUIN (levofloxacin) for the treatment of bacterial infections; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; and DURAGESIC/ (fentanyl transdermal system) CII, sold as DUROGESIC, a treatment for chronic pain that offers a novel delivery system. The Medical Devices and Diagnostics segment produces a range of products used primarily by health care professionals in the fields of cardiovascular disease; orthopaedic and neurological; blood glucose monitoring and insulin delivery; general surgery; biosurgical, and energy; professional diagnostic; infection prevention products; and disposable contact lenses. Johnson & Johnson was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Contact Information

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick New Jersey 08933
P:(732) 524-0400
Investor Relations:
(732) 524-6491

Employees

Shareholders

Other institutional37.49%
Mutual fund holders29.99%
Individual stakeholders0.13%

Top Executives

Alex GorskyChairman & Chief Executive Officer
Dominic J. CarusoChief Financial Officer & Vice President
Paulus StoffelsChief Scientific Officer
Francisco DeArmasChief Information Officer & Vice President
Michael H. UllmannVice President & General Counsel

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.